Blar i forfatter "Lakic, Tatevik G."

Viser treff 1-2 av 2

    • Legumain in Acute Coronary Syndromes: A Substudy of the PLATO (Platelet Inhibition and Patient Outcomes) Trial 

      Gregersen, Ida; Michelsen, Annika; Lunde, Ngoc Nguyen; Åkerblom, Axel; Lakic, Tatevik G.; Skjelland, Mona; Skagen, Karolina Ryeng; Becker, Richard C.; Lindbäck, Johan; Himmelmann, Anders; Solberg, Rigmor; Johansen, Harald Thidemann; James, Stefan K.; Siegbahn, Agneta; Storey, Robert F.; Kontny, Frederic; Aukrust, Pål; Ueland, Thor; Wallentin, Lars; Halvorsen, Bente (Journal article; Tidsskriftartikkel; Peer reviewed, 2020-08-15)
      <i>Background</i> - The cysteine protease legumain is increased in patients with atherosclerosis, but its causal role in atherogenesis and cardiovascular disease is still unclear. The aim of the study was to investigate the association of legumain with clinical outcome in a large cohort of patients with acute coronary syndrome.<p><p> <i>Methods and Results</i> - Serum levels of legumain were ...

    • Pentraxin-3 vs C-reactive Protein and Other Prognostic Biomarkers in Acute Coronary Syndrome: A Substudy of the Platelet Inhibition and Patients Outcomes (PLATO) Trial 

      Kontny, Frederic; Andersen, Thomas; Ueland, Thor; Åkerblom, Axel; Lakic, Tatevik G.; Michelsen, Annika; Aukrust, Pål; Bertilsson, Maria; Becker, Richard C.; Himmelmann, Anders; James, Stefan K.; Siegbahn, Agneta; Storey, Robert F.; Wallentin, Lars (Journal article; Tidsskriftartikkel; Peer reviewed, 2019-04-24)
      <i>Aims</i>: We investigated the dynamics, associations with patient characteristics, other biomarkers, and clinical outcomes of pentraxin 3 in acute coronary syndrome.<p><p> <i>Methods and results</i>: In multivariate analyses, pentraxin 3 measured in 5154 patients randomised in the Platelet Inhibition and Patients Outcomes (PLATO) trial (NCT00391872) was compared with leukocytes, high-sensitivity ...